Introduction
Tacrolimus is a potent immunosuppressive agent and a calcineurin inhibitor, which has recently come into clinical use as an anti-rejection agent in the field of transplantation therapy. The side effects of this drug closely resemble those of cyclosporin 1), including tremor, headache, paresthesia, blurred vision, photophobi a, tinnitus, nausea, vomiting, hypertension, hyperglycemia, hyperkalemia and hyperuricemia. Cardiac complications of tacrolimus have been reported in the form of cardiac hypertrophy 2), bradyarrhythmias 3)and tachyarrhythmias 4). In this communication we describe a familial amyloid polyneuropathy (FAP) patient 5) who received partial liver transplantation and suffered from brady-and tachycardia possibly caused by tacrolimus.
Materials
and Methods
I. Case Report
The patient was a 47-year-old woman with a 7-year history of FAP, who presented with polyneuropathy and auto-Asahi, Matsumoto-shi, Nagano, 390-8621 Japan nomic disturbances. Amyloid deposition was seen on rectal biopsy and DNA analysis showed an abnormal transthyretin with a valine to methionine substitution at position 30. Routine laboratory tests including renal function were unremarkable. Electrocardiogram (ECG) revealed left axis deviation, first-degree AV block, corrected QT interval (QTc) of 447 msec and QS waves in leads V 1 -V 3 ( Fig. 1 A) , all of which are characteristic findings of amyloid heart in FAP5). Echocardiography showed left ventricular symmetrical thickening and normokinesis. After the approval from the ethics committee of the university she underwent partial liver transplantation using a graft from a living donor6). After tran splantation, oral methylpredonisolone 10mg and tacrolimus 3. 2mg to 5. 6mg/day b.i.d were added for immunosuppression to oral suipiride 300mg/day, rebamipide 300mg/day and droxidopa 600mg/day. On the 77th day, an ECG showed QTc of 498 msec. On the 80th day she experienced syncope. ECG taken immediately revealed additional right bundle branch block and QTc was 509 msec (Fig. 1 B) . The next day she suffered another attack and ECG monitoring disclosed wide QRS tachycardia (240 beats/minute). On the 82nd day wide ORS tachycardia (206 beats/minute) reappeared ( Fig. 1 C) . All laboratory data, including hematocrit, serum potassium and albumin, did not remarkably change in last 4 weeks and cardiac function on echocardiography was well preserved.
Assay of tacrolimus
Trough blood tacrolimus concentration were assayed using microparticle enzyme immunoassay (MEIA) and an IMx autoanalyzer7). Tacrolimus dosage was adjusted to attain a trough blood concentration ranging from 10 to 18 ng/mL.
Clinical course and drug administration
During the following one week she suffered two episodes of dizziness and ECG showed marked bradycardia (35-46 beats/minute ; Fig. 1 D) . Sinus bradycardia or sinoatrial block was suspected. Although the morning trough levels of tacrolimus were not very high (Table 1 ) , this drug was suspected of producing the life-threatening arrhythmia and was discontinued on the 82nd day. From the 83rd day oral cyclosporin 150 to 200mg b.i.d. were newly added to her predonisolone. Since then, tachyarrhythmias have not recurred (Fig. 2 ) . ECG showed QTc of 482-490 msec. Permanent pacemaker was implanted on the 89th day for prolonged sinus bradycardia.
Discussion
Potentially toxic effects of tacrolimus on the heart were demonstrated experimentally in rabbits8) and baboons9), and chest discomfort and/or palpitation have occasionally been reported in humans10). In addition, clinically apparent cardiotoxicity was described in 5 pediatric transplants showing hypertrophic cardiomyopaithy11), which almost resolved after discontinuation of tacrolimus. Recently tacrolimus-induced sinus bradycardia3) and QT prolongation with ventricular tachycardia4,12) were reported, though no relationship to the plasma concentration of tacrolimus was suggested. Tacrolimus has been shown to increase in the intracellular cal-cium2,3) and to prolong the action potential duration, which might induce the prolongation of conduction and result in conduction block. In our patient transient RBBB, marked bradycardia (possibly sino atrial block) and wide QRS tachycardia were possibly due to conduction block caused by the use of tacrolimus. Because tachyarrhythmias have newly developed on 80th day after liver transplantation with tacrolimus regimen, and have diminished after change of tacrolimus administration to cyclosporin, we speculated that tachycardia were possibly caused by tacrolimus. Because sinus bradycardia, however, had prolonged one week after tacrolimus cessation, we thought it possibly persistent and decided to implant permanent pacemaker. Why the lethal arrhythmias developed in stable period after liver transplantation and tacrolimus administration. Tacrolimus-induced sinus bradycardia3) or QT prolongation with ventricular tachycardid4,12) developed after the intravenous first dose. However, leukoencephalopathy developed after three months to one year after tacrolimus prescription for immunosuppression therapy of three transplanted pa-tients, and it resolved spontaneously upon decreasing the dose13). It was unclear why such a syndrome developed with tacrolimus therapy.
In FAP patients amyloid deposition mainly involves the subendocardial specialized conducting tissue, and conduction disturbances are frequently observed, but rhythm disturbances with tachycardia rarely appear5). Because the administration of tacrolimus was not overdoses from the doses and blood concentration of tacrolimus, the amyloid heart in FAP might be more sensitive to the intracellular calcium accumulation effect of tacrolimus.
Liver transplantation has become a valuable treatment for FAP and tacrolimus is highly effective for the prevention of liver allograft rejection. When tacrolimus is used in FAP patients with amyloid heart, however, cardiac side effects including arrhythmia need to be monitored very carefully.
